Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M

VERACYTE, INC.

2025-FY EPS reported $0.82 revenue$517,145,000

FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.
Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.
Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.
FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).
CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.